An Lp(a)-adjusted polygenic risk score (PRS) for atherosclerotic cardiovascular disease (ASCVD) may improve risk assessment for myocardial infarction (MI) when used alongside traditional risk factors.
Educational Partners and Supporters
AstraZeneca has provided a sponsorship grant towards this independent programme.
(Founding Partner)
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.
